SciSparc Ltd News - SPRC

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Form POS AM - Post-Effective amendments for registration statement

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

No Immediate Effect on Nasdaq Listing or Trading of the Company’s Ordinary Shares TEL AVIV, Israel, Jan. 15...

SciSparc: AutoMax Enters the Direct Import Market with a $13 Million First Shipment of JAC Electric Vehicles

TEL AVIV, Israel, Jan. 13, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc...

SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results

TEL AVIV, Israel, Jan. 07, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment

TEL AVIV, Israel, Jan. 06, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc...

Form F-4/A - Registration of securities, foreign private issuers, business combinations: [Amend]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder

TEL AVIV, Israel, Dec. 31, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc...

Form 425 - Prospectuses and communications, business combinations

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation

TEL AVIV, Israel, Dec. 26, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

SciSparc Provides Updates on Status of Spin-off of its Advanced Clinical Stage Pharmaceutical Portfolio to a Publicly Traded Company

According to the LOI, SciSparc’s pharmaceuticals assets are valued at approximately US$11.6 million TEL AVIV...

tw0122 2 weeks ago

Regained compliance news .79

👍️0

subslover 3 weeks ago

SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results
TEL AVIV, Israel, Jan. 07, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that MitoCareX Bio Ltd. (“MitoCareX”), its joint venture with Dr. Alon Silberman, is expanding its research and development efforts into pancreatic cancer following encouraging initial in-vitro results.

MitoCareX, which focuses on drug discovery and the development of cancer therapeutics targeting the mitochondrial SLC25 protein family, recently achieved positive results using pancreatic cancer cell lines. These findings build on MitoCareX’s earlier success in developing a computationally advanced drug discovery platform that virtually screened millions of small molecules, identifying several as potential anti-cancer treatments.

By leveraging its in-vitro screening systems related to mitochondria, MitoCareX corroborated the anti-cancer biological activity of several small molecule structures discovered out of millions of them that were virtually screened the addition of pancreatic cancer to its existing focus on non-small cell lung cancer marks a significant expansion of its therapeutic ambitions.

Additionally, MitoCareX continues its efforts to create a predictive artificial intelligence (AI) model, utilizing the extensive virtual data generated during its discovery processes. This model is designed to efficiently navigate broader chemical spaces, with the goal of uncovering more novel anti-cancer scaffolds targeting the SLC25 protein family.

Pancreatic cancer remains one of the most aggressive and difficult-to-treat cancers, with a significant unmet medical need. According to the American Cancer Society, the 5-year survival rate for pancreatic cancer is just 12% (as of 2023), one of the lowest among all cancers. It is the third leading cause of cancer-related deaths in the United States.

👍 1

LowFloatLopes 3 weeks ago

Boom!

👍 1

glenn1919 3 weeks ago

sprc..........................................................a/h

👍️0

subslover 3 weeks ago

I am pretty sure that the $200 mil PP on CCCC is finally over. 😇

👍️0

B RY 3 weeks ago

Sprc, cccc, and lucy are my main interest currently and possible long term holds. You and I are very familiar with all 3. Time will tell, but I think all 3 will have a good 2025.

👍️0

subslover 3 weeks ago

B RY, hey buddy! Thank you for this info! The company must have finally gotten its act together. I bet we see many more nice PR's🥰

👍️0

B RY 3 weeks ago

My fingers were working faster than my mind. 3/6/2024 was last year's 13g filing, lol. I did my reading about their business collaborations first and like the business model for strong growth. I hold it for awhile and see what develops.

👍️0

B RY 3 weeks ago

Hi subs! I'm in after I checked finviz and saw new insitutional interest(13g) filed today with a nice drop in price from the high this morning.

https://fintel.io/so/us/sprc

👍️0

Invest-in-America 3 weeks ago

SPRC: And get ready to sell the NEXT half???

👍️0

LowFloatLopes 3 weeks ago

Back in 1.22

👍️0

Invest-in-America 3 weeks ago

SPRC: You may have to WAIT quite awhile for THAT price, Homeboy!!! (Maybe like DAYS!!)

👍️0

LowFloatLopes 3 weeks ago

I'll be back at $1.28

👍️0

LowFloatLopes 3 weeks ago

Sold other half $1.70

👍️0

Invest-in-America 3 weeks ago

SPRC: RE-launced at 212%!!!

👍️0

Invest-in-America 3 weeks ago

SPRC: 2nd halt at 180%!!!

👍️0

LowFloatLopes 3 weeks ago

I sold half at $1.20

👍️0

Mojocash 3 weeks ago

Took profit to early! Best of Luck everyone!

👍️0

LowFloatLopes 3 weeks ago

Halt!

👍️0

Invest-in-America 3 weeks ago

SPRC: UN-halted!!! (I want a Planet JUPITER run!!!!)

👍️0

Invest-in-America 3 weeks ago

SPRC: Halted.

👍️0

subslover 3 weeks ago

Great job!😷

👍️0

Mojocash 3 weeks ago

Great run. Target met. 2 bags.

👍️0

subslover 3 weeks ago

$1.26 on the news. SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment
TEL AVIV, Israel, Jan. 06, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today as part of its ongoing collaboration with Clearmind Medicine Inc. (“Clearmind”) (Nasdaq: CMND) (FSE: CWY0), a biotechnology company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated mental health problems, the publication of a European patent application submitted by Clearmind under the European Patent Office for innovative combination therapy of MEAI and N-Acylethanolamines, to binge behavior including alcohol consumption, eating, tobacco consumption, shopping and sexual conduct.

Under this collaboration, SciSparc and Clearmind are researching innovative combination therapies that integrate psychedelic molecules with the N-acylethanolamines family, including Palmitoylethanolamide. To date, thirteen patents related to this collaboration have been filed by Clearmind in the United States as well as in several other global jurisdictions.

About SciSparc Ltd. (Nasdaq: SPRC):

SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer's disease and agitation; and SCI-210 for the treatment of autism and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seeds’ oil-based products on the Amazon.com Marketplace.

👍️0

glenn1919 3 weeks ago

SPRC......https://stockcharts.com/h-sc/ui?s=SPRC&p=W&b=5&g=0&id=p86431144783

👍️0

Mojocash 3 weeks ago

Dollar break coming!!!!

👍️0

Mojocash 3 weeks ago

Great move on small volume

👍️0

glenn1919 3 weeks ago

SPRC...............https://stockcharts.com/h-sc/ui?s=SPRC&p=W&b=5&g=0&id=p86431144783

Tourette Alzheimer's and Chinese EV imports

👍️0

Mojocash 1 month ago

This thing is killing it today from 39. Loving this play.

👍️0

glenn1919 1 month ago

SPRC...................https://stockcharts.com/h-sc/ui?s=SPRC&p=W&b=5&g=0&id=p86431144783

👍️0

Mojocash 1 month ago

A 10.6 mill o/s and trades 230 million and only up 133%. Scratching my head.

👍️0

Mojocash 1 month ago

This should pop hard... volume is epic

👍️0

Mojocash 1 month ago

200 million in volume! Should be a lot higher in price..... you'd think....

👍️0

subslover 1 month ago

Once a pump = always a pump.😇

👍️0

tw0122 1 month ago

Looks like pump close to over .72 +'225% from pharma divested to auto imports

👍️0

subslover 1 month ago

SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation
TEL AVIV, Israel, Dec. 26, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), announced that AutoMax Motors Ltd., (“AutoMax”), a leading automotive importer and distributor in Israel with which the Company has entered into an agreement and plan of merger, received its first shipment of vehicles manufactured by Anhui Jianghuai Automobile Group Co., Ltd. (“JAC Motors”), a globally recognized Chinese automotive company. This marks a significant milestone in AutoMax’s direct import and distribution operations, launched under agreements signed earlier this year with JAC Motors.

The shipment follows regulatory approvals for direct importation and positions AutoMax to begin marketing and sales activities for JAC Motors vehicles across Israel.

SciSparc has provided financial support to AutoMax, which SciSparc believes helped provide AutoMax with resources to facilitate the transaction with JAC Motors. Further, as part of its growth strategy, AutoMax entered into a merger agreement with the Company in April 2024, that if completed would pave the way for SciSparc’s expansion into the automotive sector. The merger is subject to closing conditions, including the approval of the shareholders of each of the Company and AutoMax.

About SciSparc Ltd. (Nasdaq: SPRC):

👍️0

Awl416 4 months ago

Fall for it if ya want

SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX

👍️0

Monksdream 4 months ago

SPRC new 52;week low

👍️0

Monksdream 4 months ago

SPRC new 52 week low

👍️0

Monksdream 5 months ago

SPRC new 52 week low

👍️0

Awl416 5 months ago

Talk about jumping off a cliff…

👍️0

glenn1919 5 months ago

SPRC.............................https://stockcharts.com/h-sc/ui?s=SPRC&p=W&b=5&g=0&id=p86431144783

👍️0

Pastor Phil 5 months ago

I’m sold out

👍️0

webprods 5 months ago

Great news today. 1.63 coming

👍️0

webprods 5 months ago

32.63% pm . Actual

👍️0

Pastor Phil 5 months ago

Up over 30% premarket

👍️0

webprods 5 months ago

OS is only 7.36 million. 7,360,000

👍️0

webprods 5 months ago

Here you are. As of August 15, 2024, SciSparc Ltd. (SPRC) stock had 7.36 million shares outstanding. The company's public float was 2.45 million. Good luck. Closer to merger higher share price. I think that double dollars is possible

👍️0

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

SciSparc Ltd (SPRC)

Empower your portfolio: Real-time discussions and actionable trading ideas.

SPRC News

Form POS AM - Post-Effective amendments for registration statement

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

SciSparc: AutoMax Enters the Direct Import Market with a $13 Million First Shipment of JAC Electric Vehicles

SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment

Form F-4/A - Registration of securities, foreign private issuers, business combinations: [Amend]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder

Form 425 - Prospectuses and communications, business combinations

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

SciSparc Provides Updates on Status of Spin-off of its Advanced Clinical Stage Pharmaceutical Portfolio to a Publicly Traded Company

SPRC Discussion

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

SciSparc Ltd (SPRC) News

SciSparc Ltd (SPRC)

Empower your portfolio: Real-time discussions and actionable trading ideas.

SPRC News

Form POS AM - Post-Effective amendments for registration statement

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

SciSparc: AutoMax Enters the Direct Import Market with a $13 Million First Shipment of JAC Electric Vehicles

SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment

Form F-4/A - Registration of securities, foreign private issuers, business combinations: [Amend]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder

Form 425 - Prospectuses and communications, business combinations

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

SciSparc Provides Updates on Status of Spin-off of its Advanced Clinical Stage Pharmaceutical Portfolio to a Publicly Traded Company

SPRC Discussion

Your Recent History

Company

Business

Popular

Get The App

Go Ad-Free